

July 30, 2018
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

**Revised Medical Practice Guidelines 2018 for Healthcare Professionals
newly includes anti-cancer agent TREAKISYM[®], as standard-of-care therapy**

TOKYO, Japan, July 30, 2018 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo, "Symbio") announced today that anti-cancer agent, TREAKISYM[®] (non-proprietary name: bendamustine hydrochloride), has been newly included as a standard-of-care option in the Guidelines for Tumors of Hematopoietic and Lymphoid Tissues 2018 ("Guidelines") issued by JSH (Japan Society of Hematology) on July 20, 2018.

The Guidelines, which are a major revision since the 2013 edition, have been significantly revised to reflect recent dramatic advances in new treatment methods for hematopoietic tumors based on evidence accumulated by experts in hematopoietic oncology practice. Under the Guidelines, TREAKISYM[®] now covers mantle cell lymphoma, chronic lymphocytic leukemia, and relapsed refractory low-grade B-cell non-Hodgkin's lymphoma (relapsed refractory low-grade NHL), and has been newly included as a first-line treatment option for patients with low-grade NHL.

The inclusion of TREAKISYM[®] in the Guidelines for all approved indications establishes its position, both in reputation and practice, as a standard treatment for malignant lymphoma. It is expected to replace conventional standard therapies and to increase its penetration in the market.

In the field of first-line low-grade NHL, approved in December 2016, TREAKISYM[®] (BR Therapy) has achieved fifty percent (50%) market share in less than a year and is steadily replacing R-CHOP as the conventional standard therapy.

By further promoting the appropriate use of TREAKISYM[®] in the treatment of malignant lymphoma, Symbio shall continue to develop its business to enhance its corporate value by making further contributions to patients and healthcare settings.

[Contact]

Investor Relations
Tel: +81 (0)3 5472 1125

About TREAKISYM®

TREAKISYM® (non-proprietary name: bendamustine hydrochloride), a cytocide anti-cancer drug first used in Germany in the 1970s, is now widely used in more than 50 countries with indications for low-grade non-Hodgkin's lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia.

- TREAKISYM® Intravenous Infusion 100 mg was approved in October, 2010 for manufacturing and marketing for the indication of relapsed/refractory low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma in Japan.
- TREAKISYM® was approved for the additional indication of chronic lymphocytic leukemia in Japan in August, 2016.
- TREAKISYM® Intravenous Infusion 25 mg, a standard low-dose product, was approved for manufacturing and marketing in Japan in September, 2016.
- TREAKISYM® was approved for the additional indication of first-line treatment of low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma in Japan in December, 2016.
- TREAKISYM® is currently under Phase 3 clinical study for indication of diffuse large B cell lymphoma and accumulating cases.

TREAKISYM® has been marketed by SymBio through its partnership with Eisai Co., Ltd. since December, 2010.

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May, 2016 SymBio incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). SymBio's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.